Description: Palbociclib D8 (PD-0332991 D8; PD 0332991 D8) is the octa-deuterated form of Palbociclib. Palbociclib (Ibrance, PD-0332991) is the first CDK4/6 inhibitor approved by FDA in 2017 for cancer treatment.

References:Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.

Related CAS#: 571190-30-2 (free base); 1628752-83-9 (Palbociclib D8); 827022-33-3 (isethionate salt); 827022-32-2 (HCl); 2366269-23-8 (Palbociclib-propargyl)

Publications Citing Use of InvivoChem Palbociclib (PD-0332991): Ann Transl Med 2022;10(13):746 | .21037/atm-22-2830.

纯度：≥98%

CAS：1628752-83-9